Managing Editor of the journal Lupus, Chairman of the Antiphospholipid Syndrome Laboratory Diagnostics and Trends Task Force, Executive Committee Member of the APS alliance for clinical tri
Presence of anti-PS/PT IgG or IgM antibodies indicates a high risk category of patients
Antiphospholipid antibodies are not directed against phospholipids, but rather to phospholipid-protein complexes. Recent evidence suggests that antibodies to the complex of PS and PT (PS/PT) identifies a distinct subset of patients with very high likelihood of adverse events. Antibodies targeted to either PS or PT yield less clinically relevant information as antibodies towards the PS/PT complex.
Recent studies have shown that the risk of thrombotic events increases with the number of positive test results in APS patients and aPL carriers. Triple positivity for LAC, anti-β2GP1, and PS/PT demonstrated the highest diagnostic accuracy out of 23 possible combinations of aPL tests.
Inclusion of PS/PT testing into routine testing can improve patient outcome.
Anti-β2GP1 domain 1 antibodies are highly specific for the diagnosis of APS and may help support therapeutic decision making
Anti-β2GP1 antibodies target multiple epitopes in the same molecule. A growing body of evidence indicates that domain 1 is the most relevant epitope targeted by anti-β2GP1 antibodies in patients with APS. Many studies have shown that anti-domain 1 antibodies identify a distinct population of patients with a high risk of thromboembolic events, despite therapy. In addition, carriers are high risk to develop a first thromboembolic event.
It is over half a century since haemoglobin A1c (HbA1c) was recognised by medical professionals; the importance of HbA1c to the long term health of people with diabetes was clearly demonstra...
The implementation of a preemptive pharmacogenomics (PGx) program in a hospital setting requires a multidisciplinary approach to ensure seamless integration of each stage of the process for...
The implementation of a preemptive pharmacogenomics (PGx) program in a hospital setting requires a multidisciplinary approach to ensure seamless integration of each stage of the process for...
Join us in this enlightening session to deepen your understanding of qualifications and their transformative impact on risk management and regulatory adherence. Gain actionable insights that...
Ever wonder what you’re missing in your data? The sheer complexity of today’s flow and mass cytometry datasets demands automated solutions. Machine learning plugins only provide...
Loading Comments...
Please update your information
Certificate of Attendance
Thank you for choosing Labroots. Please note that a Certificate of Attendance does NOT count towards Continuing Education Credits.